RT Journal Article
SR Electronic
T1 Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003–2006
JF Sexually Transmitted Infections
JO Sex Transm Infect
FD BMJ Publishing Group Ltd
SP 505
OP 508
DO 10.1136/sextrans-2013-051490
VO 90
IS 6
A1 Camille E Introcaso
A1 Eileen F Dunne
A1 Susan Hariri
A1 Gitika Panicker
A1 Elizabeth R Unger
A1 Lauri E Markowitz
YR 2014
UL http://sti.bmj.com/content/90/6/505.abstract
AB Background A vaccine is available to prevent human papillomavirus (HPV) 6, 11, 16 and 18; in the prevaccine era, seropositivity to vaccine types is a measure of natural exposure. Methods We describe HPV seropositivity in the USA among 14–59-year-olds using the 2003–2006 National Health and Nutrition Examination Surveys. Results Seropositivity to HPV 6, 11, 16 and 18 was 17.5%, 6.8%, 15.1% and 5.9%, respectively, among women, and 7.0%, 2.4%, 5.2% and 1.5%, respectively, among men. Overall in both sexes, seropositivity was 22.5% for any vaccine type (31.8% in women and 12.9% in men), but substantially lower for three or more types (1.7% overall, 2.8% in women and 0.6% in men). Conclusions Almost a quarter of the participants were seropositive to any HPV vaccine type but few were seropositive to at least three vaccine HPV types in the prevaccine era. Further study is needed to assess if seropositivity would be useful as a biological marker of vaccination.